NCT01380145 · REGISTRY CONDITION SEARCH

MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1
Status at capture: COMPLETED
Registry last update: 2022-10-25

This was an open-label, single-arm, pilot study of the recombinant MAGE-A3 protein plus the immunological adjuvant AS15 (recMAGE-A3 + AS15) in subjects with symptomatic multiple myeloma who had completed induction therapy with at least a Very Good Partial Response (VGPR) by the International Myeloma Working Group (IMWG) criteria and who were eligible for high-dose chemotherapy with autologous stem cell transplant (auto-SCT). The primary objective was to determine the safety and tolerability of immunizations when administered prior to stem cell mobilization and multiple times after stem cell reinfusion. Secondary objectives were to assess the humoral and cellular immunogenicity and clinical outcomes of immunization.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Assessment of Safety of recMAGE-A3 + AS15

→

outcome · POSTED

Induction or Augmentation of MAGE-A3-Specific Humoral Immunity

→

outcome · POSTED

Induction or Augmentation of MAGE-A3-Specific Cellular Immunity

→

outcome · POSTED

Assessment of Tumor Response

→

outcome · POSTED

Assessment of Survival and Time to Subsequent Therapy

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Symptomatic multiple myeloma, ISS stage 1, 2 or 3 within 12 months of starting therapy. 2. Completion of induction therapy with VGPR, or better, by IMWG criteria. All induction myeloma therapy (oral or intravenous, including steroids) must have been discontinued for 3 weeks prior to the first immunization. Subjects did not need to have measurable disease at the time of the screening visit. 3. Signed separate informed consent for stem cell mobilization and high-dose chemotherapy/auto-SCT, and was found to be eligible for SCT by standard institutional criteria. 4. MAGE-A3 expression determined by immunohistochemistry (IHC) present in a bone marrow specimen or plasmacytoma specimen. 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. 6. The following laboratory parameters within the ranges specified: * Neutrophil count: ≥ 1.5 x 109/L * Lymphocyte count: ≥ 0.5 x 109/L * Platelet count: ≥ 50 x 109/L * Serum creatinine: ≤ 2 mg/dL * Serum bilirubin: \< 1.5 x the upper limit of normal (ULN) * Aspartate and alanine aminotransferase (AST and ALT): \< 2 x ULN * Hemoglobin: ≥ 8.0 g/dL * International normalized ratio (INR): ≤ 1.5 * Partial thromboplastin time: ≤ 1.5 x ULN (unless known history of anti-phospholipid antibody or lupus anticoagulant) 7. Age ≥ 18 years. 8. Able and willing to give valid written informed consent. Exclusion Criteria: 1. Prior treatment with melphalan (Alkeran®), other than 1 cycle (4 days) of oral melphalan. 2. Prior autologous or allogeneic SCT. 3. Prior immunization against MAGE-A3 or other cancer-testis antigens. 4. Concurrent malignancies, except for treated non-melanoma skin cancer and cervical carcinoma in situ. 5. Known immunodeficiency, human immunodeficiency virus (HIV) positivity, or active hepatitis B or C. 6. Known allergy or history of life-threatening reaction to G-CSF or GM-CSF. 7. History of autoimmune disease (eg., rheumatoid arthritis, lupus), other than vitiligo, diabetes, or treated thyroiditis. 8. History of severe allergic reactions to vaccines or unknown allergens. 9. History of myocardial infarction, angina, congestive heart failure, ventricular tachyarrhythmia, stroke or transient ischemic attack within the previous 6 months. 10. Other serious illnesses or co-morbid conditions (e.g., serious infections requiring antibiotics, bleeding disorders, other heart or lung conditions) that, in the opinion of the investigator, made the subject inappropriate for high-dose melphalan and auto-SCT. 11. Pregnancy and breastfeeding. 12. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first immunization. 13. Mental impairment that may have compromised the ability to give informed consent and comply with the requirements of the study. 14. Lack of availability for immunological and clinical follow-up assessments.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15.
intervention Names
Biological: recMAGE-A3 Protein + AS15 Adjuvant
label
recMAGE-A3 Protein + AS15 Adjuvant
type
EXPERIMENTAL

interventions

arm Group Labels
recMAGE-A3 Protein + AS15 Adjuvant
description
recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
name
recMAGE-A3 Protein + AS15 Adjuvant
other Names
Antigen-specific cancer immunotherapeutic (ASCI)
type
BIOLOGICAL

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 13
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Analysis of treatment-emergent adverse events (TEAEs) reported from clinical laboratory tests, physical examinations, and vital signs, with severity graded according to the NCI CTCAE, Version 4.0.
measure
Assessment of Safety of recMAGE-A3 + AS15
time Frame
Continuously for up to 14 months

secondary Outcomes

description
Humoral immunity was determined by enzyme-linked immunosorbent assay (ELISA) to measure the presence of circulating antibodies to MAGE-A3. Titers against an antigen were considered significant if they were \>100. Induction of responses was considered significant if there was a change from undetectable (\<100) to detectable (\>100) or if there was an at least 4-fold increase in titers over time.
measure
Induction or Augmentation of MAGE-A3-Specific Humoral Immunity
time Frame
Baseline, first immunization, and first and second leukopheresis prior to auto-SCT; Days 31, 73, 194, 284, and 374 after auto-SCT
description
Cellular immunity was determined by enzyme-linked immunosorbent spot assay (ELISPOT) or intracellular flow cytometry to determine peripheral blood levels of interferon gamma-producing CD4+ and CD8+ T cells specific for MAGE-A3. Results were considered significant if \> 50 spots and \> 2 times the number of spots to negative control were observed.
measure
Induction or Augmentation of MAGE-A3-Specific Cellular Immunity
time Frame
Baseline, first immunization, and first and second leukopheresis prior to auto-SCT; Days 31, 73, 194, 284, and 374 after auto-SCT
description
Tumor responses were evaluated using appropriate imaging methods and were categorized according to the IMWG criteria, which includes the following response designations: Complete Response (CR): negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, \<5% plasma cells in bone marrow; Stringent CR (sCR): CR + normal free light chain (FLC) ratio and absence of clonal cells in bone marrow; Very Good Partial Response (VGPR): Serum/urine M-component detectable by immunofixation but not electropheresis OR ≥90% reduction in serum M-component + urine M-component \<100 mg/24 hrs; Partial Response (PR): ≥50% reduction of serum M-protein and reduction in 24-hr urinary M-protein by ≥90% or to \<200 mg/24 hrs Stable disease: not response or progression
measure
Assessment of Tumor Response
time Frame
At 3 and 12 months after auto-SCT
description
Progression-free survival (PFS) was calculated as the date from first immunization to first observation of disease progression or death due to any cause, censored on the start date of subsequent therapy or at the last date of disease assessment for subjects without a PFS event. Overall survival (OS) was calculated as the date from first immunization to death due to any cause, censored at the date of last follow-up for subjects who were alive at the time of the analysis. Time to subsequent therapy was calculated as the date from first immunization to start of subsequent therapy for myeloma, censored at the date of death or last follow-up for subjects who did not receive subsequent therapy.
measure
Assessment of Survival and Time to Subsequent Therapy
time Frame
Continuously on study and for up to 5 years post-study

Full study description

brief Summary: This was an open-label, single-arm, pilot study of the recombinant MAGE-A3 protein plus the immunological adjuvant AS15 (recMAGE-A3 + AS15) in subjects with symptomatic multiple myeloma who had completed induction therapy with at least a Very Good Partial Response (VGPR) by the International Myeloma Working Group (IMWG) criteria and who were eligible for high-dose chemotherapy with autologous stem cell transplant (auto-SCT). The primary objective was to determine the safety and tolerability of immunizations when administered prior to stem cell mobilization and multiple times after stem cell reinfusion. Secondary objectives were to assess the humoral and cellular immunogenicity and clinical outcomes of immunization.
detailed Description: Subjects were enrolled sequentially following confirmation of eligibility criteria, including International Staging System (ISS) stage 1, 2, or 3 multiple myeloma with MAGE-A3 tumor antigen expression. Subjects received a total of 8 immunizations with 300 µg of recMAGE-A3 + AS15. The first immunization was administered approximately 6 to 15 weeks prior to auto-SCT (Day 0), with subsequent immunizations administered every 3 weeks (± 3 days) starting 10 days after auto-SCT (ie, Days 10, 31, 52, 73, and 94). Two additional immunizations were administered at 3-month intervals (± 7 days, ie, Days 180 and 270). No dose adjustments were allowed. Platelet counts must have been ≥ 50 x 10E9/L prior to immunization, with blood product transfusions permitted as necessary. The process for auto-SCT comprised the following: (1) up to 3 steady-state leukopheresis procedures to collect and freeze a sufficient quantity of peripheral blood mononuclear cells (PBMCs), with the first leukopheresis performed 3 weeks (± 6 days) after the first immunization; (2) stem cell mobilization with cyclophosphamide, granulocyte-colony stimulating factor (G-CSF) and/or plerixafor; (3) high-dose melphalan (total dose 200 mg/m2) on Days -3 through -1; (4) auto-SCT on Day 0; and (5) re-infusion with thawed PBMCs on Day 3.

Source references

references

citation
Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ. Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer Immunol Res. 2019 Apr;7(4):658-669. doi: 10.1158/2326-6066.CIR-18-0198. Epub 2019 Feb 11.
pmid
30745365
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-8fba97f0ce947852ed3d
requested nct id
NCT01380145
primary nct id
NCT01380145
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
d8a97e1432bddfc66cb640a621b00ed945ca153c717a759116a2a5baa096e793
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-8fba97f0ce947852ed3d
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01380145
occurrences
context exact
NCT01380145
end
11
exact text
NCT01380145
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/475/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
f8b10c8af0f38bfff011ec295a4bf73cb63904a60c2deedbdd1e903240935269
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice